Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102


Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group.

Sung L, Aplenc R, Alonzo TA, Gerbing RB, Lehrnbecher T, Gamis AS.

Blood. 2013 May 2;121(18):3573-7. doi: 10.1182/blood-2013-01-476614. Epub 2013 Mar 7.


Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia.

Inaba H, Gaur AH, Cao X, Flynn PM, Pounds SB, Avutu V, Marszal LN, Howard SC, Pui CH, Ribeiro RC, Hayden RT, Rubnitz JE.

Cancer. 2014 Jul 1;120(13):1985-92. doi: 10.1002/cncr.28688. Epub 2014 Mar 26.


G-CSF and GM-CSF for treating or preventing neonatal infections.

Carr R, Modi N, Doré C.

Cochrane Database Syst Rev. 2003;(3):CD003066. Review.


Antifungal prophylaxis associated with decreased induction mortality rates and resources utilized in children with new-onset acute myeloid leukemia.

Fisher BT, Kavcic M, Li Y, Seif AE, Bagatell R, Huang YS, Zaoutis T, Torp K, Leckerman KH, Aplenc R.

Clin Infect Dis. 2014 Feb;58(4):502-8. doi: 10.1093/cid/cit781. Epub 2013 Nov 23.


Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.

Skoetz N, Bohlius J, Engert A, Monsef I, Blank O, Vehreschild JJ.

Cochrane Database Syst Rev. 2015 Dec 21;(12):CD007107. doi: 10.1002/14651858.CD007107.pub3. Review.


Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.

Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, Reiter A, Ritter J, Dworzak M, Stary J, Reinhardt D.

J Clin Oncol. 2006 Sep 20;24(27):4499-506.


Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia.

Lehrnbecher T, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Creutzig U.

Blood. 2007 Feb 1;109(3):936-43. Epub 2006 Sep 28.


Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group.

Sung L, Aplenc R, Alonzo TA, Gerbing RB, Wang YC, Meshinchi S, Gamis AS.

Int J Cancer. 2016 Nov 1;139(9):1930-5. doi: 10.1002/ijc.30236. Epub 2016 Jul 4.


International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia.

Lehrnbecher T, Ethier MC, Zaoutis T, Creutzig U, Gamis A, Reinhardt D, Aplenc R, Sung L.

Br J Haematol. 2009 Oct;147(1):125-8. doi: 10.1111/j.1365-2141.2009.07844.x. Epub 2009 Aug 5.


Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia.

Boztug H, Mühlegger N, Pötschger U, Attarbaschi A, Peters C, Mann G, Dworzak M.

Ann Hematol. 2017 Jan;96(1):99-106. doi: 10.1007/s00277-016-2833-5. Epub 2016 Oct 4.


Assessment of febrile neutropenia episodes in children with acute leukemia treated with BFM protocols.

Yilmaz S, Oren H, Demircioğlu F, Irken G.

Pediatr Hematol Oncol. 2008 Apr-May;25(3):195-204. doi: 10.1080/08880010801938231.


Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.

Pohlen M, Marx J, Mellmann A, Becker K, Mesters RM, Mikesch JH, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Krug U, Stelljes M, Karch H, Peters G, Gerth HU, Görlich D, Berdel WE.

Haematologica. 2016 Oct;101(10):1208-1215. Epub 2016 Jul 28.


Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia.

Mayer K, Hahn-Ast C, Mückter S, Schmitz A, Krause S, Felder L, Bekeredjian-Ding I, Molitor E, Brossart P, von Lilienfeld-Toal M.

Support Care Cancer. 2015 May;23(5):1321-9. doi: 10.1007/s00520-015-2621-0. Epub 2015 Jan 24.


Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.

Heath JA, Steinherz PG, Altman A, Sather H, Jhanwar S, Halpern S, Pieters R, Shah N, Steinherz L, Tannous R, Terry W, Trigg ME; Children's Cancer Group.

J Clin Oncol. 2003 Apr 15;21(8):1612-7.


Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials.

Heuser M, Zapf A, Morgan M, Krauter J, Ganser A.

Ann Hematol. 2011 Mar;90(3):273-81. doi: 10.1007/s00277-010-1069-z. Epub 2010 Sep 14. Review.


Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.

Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T.

J Clin Oncol. 2004 Nov 1;22(21):4384-93.


Supplemental Content

Support Center